Novo strikes RNA drug deal with startup Replicate
I'm PortAI, I can summarize articles.
Novo Nordisk has entered a deal with Replicate Bioscience, providing research funding and up to $550 million for new treatments targeting obesity, Type 2 diabetes, and cardiometabolic disorders. This agreement includes upfront cash and milestone payments. The collaboration follows Novo's recent challenges, including supply shortages and leadership changes, as it seeks to enhance its research pipeline and build on the success of its GLP-1 drugs, Ozempic and Wegovy. Replicate specializes in self-replicating RNA technology, aiming to develop long-lasting therapeutic proteins.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: biopharmadive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments